Epizyme's Tazverik Wins FDA Approval to Treat Follicular Lymphoma
Epizyme (NASDAQ: EPZM) on Thursday announced that had it secured Food and Drug Administration approval for the drug Tazverik to be used in previously treated adults with follicular lymphoma and an EZH2 mutation, and in relapsed or refractory patients with no other treatment options. Back in January, the regulator approved Tazverik as a treatment for metastatic or locally advanced epithelioid sarcoma patients who aren't eligible for surgery.
IMAGE SOURCE: GETTY IMAGES.
The oral medicine can reduce cancer cell growth by blocking the activity of the EZH2 enzyme. An incurable disease, follicular lymphoma develops in the white blood cells, lymphatic system, and bone marrow. It accounts for about 25% of non-Hodgkin lymphoma cases, and about 2.5 cases of it are diagnosed for every 100,000 people every year, according to the National Cancer Institute.
Source Fool.com
